Moody's Places Hospira's (HSP) Ratings on Review for Upgrade (PFE)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
AstraZeneca (AZN) Falls on Pfizer/Hospira Deal
February 5, 2015 7:33 AM ESTAstraZeneca plc (NYSE: AZN) declined Thursday after Pfizer (NYSE: PFE) and Hospira, Inc. (NYSE: HSP) announced that they have entered into a definitive merger agreement. The stock is indicated lower by over 2% pre-market.
... MorePfizer (PFE) to Acquire Hospira (HSP) in $17B Deal
February 5, 2015 7:02 AM ESTPfizer (NYSE: PFE) and Hospira, Inc. (NYSE: HSP) announced that they have entered into a definitive merger agreement under which Pfizer will acquire Hospira, the worlds leading provider of injectable drugs and infusion technologies and a global leader in biosimilars, for $90 a share in cash for a total enterprise value of approximately $17 billion. The Boards of Directors of both companies have unanimously approved the merger, which is expected to be immediately accretive upon closing, accretive by $0.10 - $0.12 per share for the first full year following the close of the... More
